Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

NCT03734588 is registered in ClinicalTrials.gov with Spark Therapeutics, Inc. as lead sponsor.

NCT NCT03734588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03734588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
Lead sponsor
Spark Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 30, 2019
Completion date
January 19, 2023
Enrollment
4 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adeno-associated virus (aav), blood coagulation disorder, blood coagulation disorders, inherited, coagulation protein disorders, factor viii (fviii), factor viii (fviii) deficiency, factor viii (fviii) gene, factor viii (fviii) protein, gene therapy, gene transfer, genetic diseases, inborn, genetic diseases, x-linked, hematologic diseases, hemorrhagic disorders, inhibitors, recombinant, vector